A new Montanide Seppic IMS 1313-adjuvanted autogenous vaccine as useful emergency tool to resolve a Salmonella enterica subsp. enterica serovar abortusequi abortion outbreak in mares.
Marica Stazi, Martina Pellegrini, Elisa Rampacci, Monica Sforna, Fabrizio Passamonti, Antonella Di Paolo, Giulio Severi.
Background. In Italy an autogenous registered vaccine, adjuvanted with aluminum hydroxide, can be subministrated to contrast the Salmonella enteric subsp. enteric serovar abortusequi infection, coupled to a specific antimicrobic treatment.
Case description. Here we report the case of an abortion outbreak by Salmonella abortusequi in Central Italy, where mares were vaccinated but immediately developed a strong local reaction, maybe due to adjuvant. Promptly, a second dose of the autogenous vaccine, substituting the aluminum hydroxide with a new generation adjuvant (Montanide Seppic IMS 1313) in lower concentration, was administrated. The new formulated vaccine did not cause any adverse outcome and conferred high protection titers against the infection. As far as we know, this is the first reported case of immunization by a vaccine adjuvanted with Montanide Seppic IMS 1313 in horses, without adverse reactions.
Conclusions. This approach may be used as a preventive strategy for further outbreaks in association with the application of recommended biosafety principles.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
